VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) and Qualigen Therapeutics (NASDAQ:QLGN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for VYNE Therapeutics and Qualigen Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VYNE Therapeutics | 1 | 3 | 0 | 0 | 1.75 |
| Qualigen Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
VYNE Therapeutics currently has a consensus target price of $4.50, suggesting a potential upside of 656.56%. Given VYNE Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe VYNE Therapeutics is more favorable than Qualigen Therapeutics.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VYNE Therapeutics | $500,000.00 | 39.60 | -$39.83 million | ($0.78) | -0.76 |
| Qualigen Therapeutics | N/A | N/A | -$6.26 million | ($7.50) | -0.17 |
Qualigen Therapeutics has lower revenue, but higher earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares VYNE Therapeutics and Qualigen Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| VYNE Therapeutics | -6,425.19% | -80.84% | -66.20% |
| Qualigen Therapeutics | N/A | N/A | -202.16% |
Volatility and Risk
VYNE Therapeutics has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.
Summary
VYNE Therapeutics beats Qualigen Therapeutics on 8 of the 12 factors compared between the two stocks.
About VYNE Therapeutics
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
About Qualigen Therapeutics
Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
